WELCOME TO The Biotechnology REPORT
Newsletter | Member Login | Signup
Home > Resources > Whitepapers > Enabling the Future of Cell & Gene Therapies through Non Proprietary Patient-Owned Data Collection
March 16, 2021
I'm For Real
Enter your details once to access all our information and resources
The Life Technology Business Unit developed ACEA’s proprietary real-time, label-free cell-based assay technology and launched the first product in 2004. The technology ismarketed globally under the xCELLigence and NovoCyte brands.
whitePaper | November 24, 2022
Smallpox was the first infectious disease for which an effective vaccine was developed. In the late 1700s, British doctor Edward Jenner devised a method to inoculate people with cowpox pus to give them immunity against smallpox, a much more deadly disease.
whitePaper | November 19, 2022
Compiling a quality regulatory submission is a basic requirement for biopharmaceutical companies. Poor quality documents could lead to rejection of a regulatory application,
whitePaper | December 22, 2022
Determining the physical titer of viral vectors has typically been accomplished using digital droplet PCR (ddPCR). Droplet-based methods, however, are challenged by matrix effects and long analysis times (up to 7 hours).
whitePaper | September 1, 2021
This report advocates for increased, long-term public investment in research and innovation, particularly in the life sciences sector, to accelerate the UK on its trajectory as a global leader in the field. This report sets out recommendations ahead of the Comprehensive Spending Review for policymakers to support innovative businesses, achieve the Prime Minister’s aim of becoming a life sciences superpower, and ultimately, deliver health benefits for Britain – and the world – for generations to come.
whitePaper | November 11, 2022
Biocontamination refers to biological contamination of products by bacteria and/or fungi, as well as the toxic by-products of these microorganisms, such as endotoxin and mycotoxins from Gram-negative bacteria and fungi, respectively.
whitePaper | December 5, 2022
The adoption of LC-MS-based multi-attribute method (MAM) analysis for routine monitoring of biotherapeutic variation has progressed greatly over the last five years.
Conference
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Welcome back!
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE